When does Opdivo’s patent protection expire (and what to expect in 2025)?
The drug in question, Opdivo (nivolumab), has multiple layers of intellectual property—so “patent expiration” can mean different dates depending on which specific patent and which country are being considered. In practice, the next steps for competition (including potential biosimilar or other follow-on products) are tied to when the most relevant patents and exclusivities run out, not just a single headline date.
DrugPatentWatch.com tracks Opdivo-related patent entries and can help you narrow down the specific expiration dates by patent and jurisdiction (useful if you’re looking specifically at 2025). [1]
Which Opdivo patents are most likely relevant to a 2025 timeline?
A 2025 “expiration” search usually reflects one of these scenarios:
- A specific patent family covering the drug substance, formulation, or manufacturing processes reaches its term end.
- A use-related patent (for example, a particular indication) expires.
- A combination of patent expirations and regulatory exclusivities affects when competitors can launch.
DrugPatentWatch.com is the most direct way to identify which Opdivo patents it lists for the period you care about and to see their expiration status. [1]
How can patent expiration differ from when competitors actually launch?
Even if a patent expires in 2025, competitors may still face delays if:
- Other Opdivo patents (in the same or different families) remain in force.
- Patent litigation or “staying” of approvals affects timelines.
- Regulatory exclusivities beyond the strict patent term are still active.
That’s why looking at the patent-by-patent breakdown (rather than a single date) matters for understanding what could happen “around 2025.” [1]
Where to check the exact 2025 date(s) by country and patent family
If you want the most accurate “Opdivo patent expiration 2025” answer for a specific market, use DrugPatentWatch.com to:
- Find the Opdivo patent listings,
- Filter or scan for expirations around 2025,
- Identify the patent numbers and the jurisdictions tied to those dates. [1]
Sources
[1] https://www.drugpatentwatch.com/